apatinib

Overview

Apatinib (also known as YN968D1) is a small-molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR-2), the primary receptor mediating tumor angiogenesis. By competitively binding to the ATP-binding site of VEGFR-2, apatinib suppresses downstream signaling pathways — including PI3K/AKT and RAS/MAPK — that drive endothelial cell proliferation, migration, and neovascularization within the tumor microenvironment. Originally developed and approved in China for advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma, apatinib has since attracted broad investigational interest across multiple solid tumor types, including hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC).

Beyond its anti-angiogenic mechanism, apatinib's pharmacological profile includes inhibitory activity against additional kinases such as c-Kit and c-Src, contributing to its pleiotropic antitumor effects. Its oral bioavailability makes it a clinically convenient agent, and its use in combination with immune checkpoint inhibitors — most notably camrelizumab — has emerged as a particularly active area of oncology research. Apatinib's interaction with hepatic metabolic enzymes, including members of the cytochrome P450 (CYP) family, is also under active investigation given the drug-drug interaction implications for patients receiving polypharmacy regimens.

Focus of Latest Publications

Recent publications highlight two principal directions of apatinib research: its expanding role in combination immuno-oncology regimens and its pharmacokinetic interactions with hepatic metabolism.

Combination immunotherapy in Solid Tumors

A significant body of recent work has focused on pairing apatinib with camrelizumab, an anti-PD-1 immune checkpoint inhibitor, exploiting the immunomodulatory synergy between VEGFR-2 blockade and T-cell checkpoint release. In metastatic clear cell renal cell carcinoma (ccRCC), a single-arm phase 2 trial (PMID: 42026573) evaluated camrelizumab plus apatinib in patients who had progressed after first-line tyrosine kinase inhibitor treatment. The study addressed a population with limited therapeutic options following front-line failure and assessed both efficacy and safety of this combination as a second-line strategy, representing an important clinical investigation in an immune checkpoint inhibitor–naïve population.

In gastric and gastro-esophageal junction adenocarcinoma, a randomized phase 3 trial (PMID: 41819560) examined camrelizumab in combination with capecitabine and oxaliplatin (CAPOX) as initial treatment, followed by a maintenance phase incorporating camrelizumab plus apatinib. The trial compared three arms — camrelizumab plus CAPOX followed by camrelizumab plus apatinib, CAPOX alone, and camrelizumab plus CAPOX followed by camrelizumab — establishing apatinib's role as a maintenance backbone alongside checkpoint inhibitor after induction chemotherapy.

For advanced hepatocellular carcinoma (aHCC), a quantitative systems pharmacology study (PMID: 41782865) characterized camrelizumab combined with apatinib as a promising treatment strategy and employed computational modeling to identify predictive biomarkers and optimize dosing. This work underscored the mechanistic rationale for combining anti-angiogenic therapy — through apatinib's VEGFR-2 inhibition — with PD-1 blockade to reshape the immunosuppressive tumor microenvironment in HCC.

Pharmacokinetic and Drug Interaction Research

A distinct line of investigation (PMID: 41825755) examined apatinib's inhibitory effect on melatonin metabolism, specifically targeting the CYP1A2 enzyme pathway. Because melatonin is primarily metabolized by CYP1A2 in the liver, and because apatinib is frequently co-administered with other medications processed by this enzyme, understanding this interaction is clinically relevant for patient safety. This study investigated apatinib's inhibitory potency and its underlying mechanistic basis using in vitro, in vivo, and computational approaches.

Key Publications

Jun Apatinib inhibits CYP1A2-mediated melatonin metabolism: in vitro, in vivo and molecular docking studies. (Chemico-biological interactions, 2026, PMID 41825755): "This study aimed to investigate the inhibitory effect of apatinib on melatonin metabolism and its underlying mechanism."
Apr Camrelizumab plus apatinib for immune checkpoint inhibitor-naive patients with metastatic clear cell renal cell carcinoma after first-line tyrosine kinase inhibitor treatment failure: a single-arm phase 2 trial. (BMC medicine, 2026, PMID 42026573): "This study evaluated the efficacy and safety of camrelizumab plus apatinib in this setting."
Apr Identification of predictive biomarkers and dose optimization for camrelizumab combined with apatinib in the treatment of advanced hepatocellular carcinoma: a quantitative systems pharmacology approach. (Frontiers in immunology, 2026, PMID 41782865): "The combination of camrelizumab and apatinib represents a promising treatment strategy for patients with advanced hepatocellular carcinoma (aHCC)."
Apr Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial. (BMJ (Clinical research ed.), 2026, PMID 41819560): "To compare camrelizumab plus capecitabine and oxaliplatin followed by camrelizumab plus apatinib (camre+CAPOX followed by camre+apa), CAPOX alone, and camrelizumab plus CAPOX followed by camrelizumab (camre+CAPOX followed by camre) as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma."